Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia

Baatarkhuu, Oidov; Gerelchimeg, Tsagaantsooj; Munkh-Orshikh, Dashchirev; Batsukh, Badamnachin; Ganbold, Sarangua; Jazag, Amarsanaa

doi:10.5005/jp-journals-10018-1260

Cited by 33 publications

(26 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Ulaanbaatar, the prevalence of HBV positivity was 32.7%, HCV 6.4%, and HBV/HDV coinfection 1.8% of the patients were diagnosed with this. Two previous studies had a higher prevalence than in our study [22][23][24][25][26]. We found that participants whose mothers were HBsAg positive had the highest risk of infection (OR 2.152; 95% CI 1.4; 3.2, p< .0001), followed by those of male gender (OR 1.703; 95% CI 1.17; 2.46, p = .005), and those who had laboratory tests (OR 1.768; 95% CI 1.14; 2.74, p = .011).…”

Section: Discussioncontrasting

confidence: 58%

Untitled

2019

Cent Asian J Med Sci

View full text Add to dashboard Cite

Objective: To determine the prevalence of hepatitis B and C infection and its risk factors in Mongolians from 10 to 40 years of age. Method: Randomly selected Mongolians underwent phlebotomy and completed a questionnaire about their medical and family history and risk factors. Participants were screened for qHBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc markers, and Anti-HCV. Results: 6811 people, 2900 (42.7%) males, and 3911 (57.3%) females participated. Most were from Ulaanbaatar (4685, 69%), with the remaining 2126 (31%) from rural areas. Seven percent were HbsAg positive, 4.2% were HCV positive. Of those10-20 years of age, 5.8% (29) had hepatitis B, 6% (17) had hepatitis C. Of those 21 to 40 years of age, 94.2% (469) had hepatitis B, and 94%(268) had hepatitis C. Children whose mother was HBsAg positive were at higher risk of HBsAg positivity (OR 2.152; 95% CI 1.4; 3.2, p < .0001) as well as those with male gender (OR 1.703; 95% CI 1.17;2.46, p < .005), those phlebotomized for lab tests (OR 1.768; 95% CI 1.14; 2.74, p = .011) ,and those immunized against hepatitis B (OR 0.508; 95% CI 0.35; 0.74, p < .0001). HCV infection was associated with history of dental procedures (OR 1.681; 95% CI 1.01; 2.79, p = .045), using glass syringes (OR 2.131; 95% CI 1.54; 2.95, p < .0001), and previously used needles (OR 2.411; 95% CI 1.09;5.29, p = .028). Conclusions: Among the Mongolian population between 10 and 40 years of age, 7.3% were HbsAg positive, 4.2% were Anti-HCV positive. The risk factors were maternal HbsAg positivity, utilization of glass syringes, reusing needles, phlebotomy for laboratory tests, receiving dental treatment, and the absence of hepatitis B immunization.

show abstract

Section: Discussioncontrasting

confidence: 58%

Untitled

2019

Cent Asian J Med Sci

View full text Add to dashboard Cite

show abstract

“…The prevalence of hepatitis C virus (HCV) infection in Mongolia is estimated to be 15.6% based on a national seroepidemiologic data. [1][2][3] Such a high rate of HCV infection in Mongolia might be due to reuse of needles before 1990, traditional medicine including bloodletting, and other unsafe medical or dental procedures. Interestingly, the most common HCV genotype in Mongolia was found to be 1b, accounting for 98% of all genotypes.…”

Section: Introductionmentioning

confidence: 99%

“…Interestingly, the most common HCV genotype in Mongolia was found to be 1b, accounting for 98% of all genotypes. 2 Since the introduction of direct-acting antivirals (DAAs) includhttp://www.e-cmh.org https://doi.org/10.3350/cmh.2020.0023…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. Methods: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12). Results: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×10 6 IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). Conclusions: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries. Clin Mol Hepatol 2020 Nov 27.

show abstract

“…Chronic infection caused by the Hepatitis B virus (HBV) is a global public health problem, with approximately 350 million people suffering from it, among which 75% are Asians [1,2]. HBV infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC).…”

Section: Introductionmentioning

confidence: 99%

Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

It is well known that both the mutation and integration of the Hepatitis B virus (HBV) are of great significance in liver cancer, however, the relationship between mutation and integration is still unclear. In this study, sequencing data from 426 previously published samples were analyzed and 5374 specific HBV mutations in cancer tissues were discovered. By comparing integrated samples and non-integrated samples, we found that the integrated samples had higher sample single nucleotide variants (SNV) positive rates and SNV numbers, as well as higher sample frequency of SNV in the X region of the HBV genome. Samples with HBV integration in the telomerase reverse transcriptase (TERT) region showed higher SNV positive rates and numbers than samples without integration. Moreover, the SNVs (209[T>G] and 531[T>C; T>G]) were seen with higher frequency in samples with integration in the TERT region. Our study showed that the occurrence of viral integration events is closely related to the occurrence of SNV, and SNV in the X region should be more directly associated with viral integration. This study provides an initial exploration of the relationship between HBV mutation and integration to help improve our understanding of the relationship between viral integration and mutation.

show abstract

Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia

Cited by 33 publications

References 113 publications

Untitled

Untitled

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study

Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma

Contact Info

Product

Resources

About